MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Spasticity: Treatment"

  • 2022 International Congress

    Real-World Clinical Utilization Differences of onabotulinumtoxinA and abobotulinumtoxinA in Upper Limb Spasticity

    M. Nelson, A. Zuzek, M. Schwartz, R. Singh (Irvine, USA)

    Objective: To compare real-world clinical utilization of onabotulinumtoxinA (onabotA) and abobotulinumtoxinA (abobotA) in the treatment of adult upper limb spasticity (ULS). Background: In the US,…
  • 2022 International Congress

    Pain reduction in adult patients with limb spasticity following a single incobotulinumtoxinA injection: an analysis of pooled data from phase 2 and 3 studies

    J. Wissel, A. Camões-Barbosa, G. Comes, M. Althaus, A. Scheschonka, D. Simpson (Potsdam, Germany)

    Objective: To assess pain relief in a large cohort of incoA-treated pts with spasticity-associated pain (SAP) using pooled data from mostly placebo-controlled phase 2/3 studies.…
  • 2022 International Congress

    Benefit of multiple incobotulinumtoxinA injections for pain reduction in adult patients with limb spasticity: an analysis of pooled data from phase 2 and 3 studies

    J. Wissel, A. Camões-Barbosa2, G. Comes, M. Althaus, A. Scheschonka, D. Simpson (Potsdam, Germany)

    Objective: To assess pain relief after multiple incoA injections in a large sample of pts with limb spasticity-associated pain (SAP) using pooled data from six…
  • 2022 International Congress

    DaxibotulinumtoxinA for Injection in Adults With Upper Limb Spasticity After Stroke or Traumatic Brain Injury: A Randomized Placebo-Controlled Study (JUNIPER)

    A. Patel, M. Munin, Z. Ayyoub, G. Francisco, T. Gross, R. Rubio, J. Kesslak (Lee's Summit, USA)

    Objective: To evaluate the efficacy and safety of 3 doses of DaxibotulinumtoxinA for Injection (DAXI) vs placebo for adults with upper limb spasticity (ULS) after…
  • MDS Virtual Congress 2021

    A phase IV, randomized, double-blind cross-over study comparing the clinical safety, efficacy and duration of abobotulinumtoxinA with onabotulinumtoxinA in adults with upper-limb spasticity: The DIRECTION study

    A. Esquenazi, Z. Ayyoub, M. Verduzco-Gutierrez, P. Maisonobe, J. Otto, A. Patel (Elkins Park, USA)

    Objective: To evaluate the safety and efficacy of abobotulinumtoxinA in comparison to onabotulinumtoxinA when used at optimized doses in approved muscles common to both products’…
  • MDS Virtual Congress 2021

    Gait Improvement in Pegzilarginase-treated Patients With Arginase 1 Deficiency: A Blinded Kinematic Analysis

    N. Foreman, G. Bubb, E. Bradford (Colleyville, USA)

    Objective: To assess the impact of pegzilarginase therapy on gait kinematics in Arginase 1 Deficiency (ARG1-D) patients. Background: High arginine levels in patients with ARG1-D…
  • MDS Virtual Congress 2021

    OnabotulinumtoxinA treatment in patients with upper limb and lower limb spasticity from the ASPIRE study

    G. Bavikatte, G. Francisco, A. Esquenazi, M. Dimyan, K. Ngo, M. Schwartz, A. Zuzek, W. Jost (Liverpool, United Kingdom)

    Objective: Examine onabotulinumtoxinA utilization in patients with upper limb (UL) and lower limb (LL) spasticity from the Adult Spasticity International Registry (ASPIRE) study to gain…
  • MDS Virtual Congress 2021

    Assessing effectiveness of abobotulinumtoxinA injections for adult lower limb spasticity in routine clinical practice: The ongoing AboLiSh study

    A. Esquenazi, R. Zorowitz, S. Ashford, F. Calvi-Gries, P. Maisonobe, S. Page, J. Jacinto (Elkins Park, USA)

    Objective: The aim of this ongoing observational study is to systematically assess goal attainment over 16 months in patients treated with ≥1 abobotulinumtoxinA (aboBoNT-A) injection(s)…
  • MDS Virtual Congress 2020

    Treatment with Botulinum Toxin for Refractory Fever caused by Severe Spasticity

    J. Lester, G. Alvarez-Resendiz, E. Klériga, F. Videgaray, G. Zambito (Huixquilucan, Mexico)

    Objective: Present a series of cases of patients with refractory fever associated to spasticity secondary to a brain or spinal cord injury who developed refractory…
  • MDS Virtual Congress 2020

    Shear wave sonoelastography is effective in detecting myofascial trigger points and spasticity

    R. Bubnov, L. Kalika (Kyiv, Ukraine)

    Objective: The aim was to evaluate effectiveness of shear wave sonoelastography is effective in detecting myofascial trigger points (MTrP) and spasticity. Background: Ultrasound (US) revolutionized…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • …
  • 7
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley